Plasma acylcarnitines and risk of cardiovascular disease: effect of Mediterranean diet interventions
Plasma acylcarnitines and risk of cardiovascular disease: effect of Mediterranean diet interventions
复制标题
DOI：
10.3945/ajcn.116.130492
复制
发表时间：
2016-06-01
影响因子：
7.1
通讯作者：
Salas-Salvado, Jordi
中科院分区：
文献类型：
--
作者：
Guasch-Ferre, Marta;Zhen, Yan;Salas-Salvado, Jordi
背景资料：以往的研究表明，代谢产物的酰基肉毒碱升高与心血管疾病（CVD）的风险增加的人群与已建立的冠心病。然而，据我们所知，这种关联尚未在一级心血管prevention.Objectives的背景下进行评估：我们评估了28种血浆酰基肉毒碱与心血管事件风险之间的关联，以及地中海饮食（MedDiet）干预的潜在修饰作用。我们使用高通量液相色谱-串联质谱法在基线和随访1年后测量血浆酰基肉毒碱，在Prevencion con Dieta Mediterranea（PREDIMED）研究中的一项病例队列研究中，无论是单独还是分类为短链、中链或长链评分，该研究是一项用于初级心血管预防的随机地中海饮食干预。随机选择的子队列（n = 751）和4.8年随访后所有可用的CVD事件病例（n = 229）均纳入本研究。在调整了年龄、性别、体重指数和其他心血管疾病风险因素后，基线短链和中链酰基胺水平最高四分位数的参与者比基线水平最低四分位数的参与者有更高的CVD风险[HR：1.80（95% CI：1.11，2.91; P趋势0.01）和1.55（95% CI：1.01，2.48; P趋势= 0.04）]。1年后短链酰基肉毒碱的增加与总CVD和中风的高风险相关。参与者与较高的基线浓度的短，中，长链酰基肉毒碱谁被随机分配到对照组有较高的风险心血管疾病比受试者与较低浓度的酰基肉毒碱谁被分配到MedDiet组。我们的数据支持这样的结论，即代谢产物谱的特征是酰基胺浓度升高与总CVD和中风的风险独立相关在CVD高风险的参与者中单独使用。MedDiet干预可能会减轻高浓度acylcamitines和CVD之间的不良关联。
Background: Previous studies have suggested that metabolite profiles of elevated acylcarnitines were associated with increased risk of cardiovascular disease (CVD) in populations with established coronary disease. However, to our knowledge, this association has not been evaluated in the context of primary cardiovascular prevention.Objectives: We evaluated the association between 28 plasma acylcarnitine species and risk of incident CVD and the potential modifying effect of Mediterranean diet (MedDiet) interventions.Design: We measured plasma acylcarnitines with the use of high throughput liquid chromatography-tandem mass spectrometry at baseline and after 1 y of follow-up, both individually and classified into short-, medium-, or long-chain scores, in a case-cohort study within the Prevencion con Dieta Mediterranea (PREDIMED) study, which is a randomized Mediterranean dietary intervention for primary cardiovascular prevention. A randomly selected sub cohort (n = 751) and all available incident CVD cases (n = 229) after 4.8 y of follow-up were included in the current study.Results: After adjustment for age, sex, body mass index, and other CVD risk factors, participants in the highest quartile of baseline short- and medium-chain acylcamitines had a higher risk of CVD than did participants in the lowest quartile [HRs: 1.80 (95% CI: 1.11, 2.91; P-trend 0.01) and 1.55 (95% CI: 1.01, 2.48; P-trend = 0.04), respectively]. Increased short-chain acylcarnitines after 1 y were associated with higher risks of total CVD and stroke. Participants with higher baseline concentrations of short-, medium-, and long-chain acylcamitines who were randomly assigned to the control group had a higher risk of CVD than did subjects with lower concentrations of acylcarnitines who were assigned to the MedDiet group.Conclusions: Our data support the conclusion that metabolite profiles characterized by elevated concentrations of acylcamitines are independently associated with risks of total CVD and stroke alone in participants at high risk of CVD. MedDiet interventions may mitigate the adverse associations shown between higher concentrations of acylcamitines and CVD.